Nomura Asset Management Co. Ltd. Sells 2,254 Shares of argenx SE (NASDAQ:ARGX)

Nomura Asset Management Co. Ltd. decreased its holdings in argenx SE (NASDAQ:ARGX) by 32.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,653 shares of the company’s stock after selling 2,254 shares during the period. Nomura Asset Management Co. Ltd.’s holdings in argenx were worth $2,862,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ARGX. Whipplewood Advisors LLC purchased a new stake in argenx in the 4th quarter worth about $37,000. Global Retirement Partners LLC raised its holdings in shares of argenx by 369.2% in the fourth quarter. Global Retirement Partners LLC now owns 61 shares of the company’s stock worth $38,000 after buying an additional 48 shares during the period. Jones Financial Companies Lllp lifted its stake in shares of argenx by 1,016.7% during the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company’s stock worth $41,000 after acquiring an additional 61 shares during the last quarter. Whittier Trust Co. of Nevada Inc. boosted its holdings in argenx by 78.6% during the 4th quarter. Whittier Trust Co. of Nevada Inc. now owns 75 shares of the company’s stock valued at $46,000 after acquiring an additional 33 shares during the period. Finally, Farther Finance Advisors LLC grew its position in argenx by 38.2% in the 4th quarter. Farther Finance Advisors LLC now owns 76 shares of the company’s stock valued at $47,000 after acquiring an additional 21 shares during the last quarter. Hedge funds and other institutional investors own 60.32% of the company’s stock.

argenx Stock Performance

argenx stock opened at $583.62 on Thursday. The business’s 50-day simple moving average is $624.55 and its two-hundred day simple moving average is $602.58. The company has a market cap of $35.46 billion, a PE ratio of -663.20 and a beta of 0.60. argenx SE has a fifty-two week low of $352.77 and a fifty-two week high of $678.21.

argenx (NASDAQ:ARGX) last issued its earnings results on Thursday, February 27th. The company reported $1.58 EPS for the quarter, beating analysts’ consensus estimates of $0.98 by $0.60. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The firm had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. As a group, analysts predict that argenx SE will post 3.13 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently weighed in on ARGX shares. Guggenheim lifted their target price on argenx from $775.00 to $1,100.00 and gave the stock a “buy” rating in a research report on Monday, March 10th. JMP Securities boosted their price objective on shares of argenx from $606.00 to $696.00 and gave the company a “market outperform” rating in a research report on Tuesday, January 14th. Piper Sandler raised their target price on shares of argenx from $620.00 to $725.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 7th. Truist Financial reiterated a “buy” rating and issued a $700.00 price target (up previously from $660.00) on shares of argenx in a report on Tuesday, January 14th. Finally, Citigroup reaffirmed an “outperform” rating on shares of argenx in a research report on Friday, February 28th. Three analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $687.00.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.